Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial

Ingrid Sääv, Olof Stephansson, Kristina Gemzell-Danielsson, Ingrid Sääv, Olof Stephansson, Kristina Gemzell-Danielsson

Abstract

Background: Today, a large proportion of early abortions are medical terminations, in accordance to the woman's choice. Intrauterine contraceptives (IUC) provide highly effective, reversible, long-acting contraception. However, the effects of timing of IUC insertion after medical abortion are not known.

Methods: Women undergoing medical abortion with mifepristone and misoprostol up to 63 days gestation and opting for IUC were randomised to early insertion (day 5-9 after mifepristone) or delayed (routine) insertion (at 3-4 weeks after mifepristone). The primary outcome was the rate of IUC expulsion at six months after IUC insertion.

Results: A total of 129 women were randomized, and 116 women had a successful IUC insertion. There was no difference in expulsion rate between early (9.7%) vs. delayed (7.4%) IUC insertion (risk difference -9.2-13.4). Furthermore, 1.5% of women randomized to early and 11.5% to delayed insertion did not attend the follow up (proportion difference 10.0%, 95% CI: 1.8-20.6%, p = 0.015), and a higher proportion of women (41%) had had unprotected intercourse prior to returning for insertion in the delayed group compared with the early group (16%) (p = 0.015). Adverse events were rare and did not differ between the groups.

Conclusions: Early insertion of IUC after medical abortion was safe and well tolerated with no increased incidence for expulsions or complications. Women were more likely to return for the IUC insertion if scheduled early after the abortion, and less likely to have had an unprotected intercourse prior to the IUC insertion. Early insertion should be offered as a routine for women undergoing first trimester medical abortion.

Trial registration: ClinicalTrials.gov NCT01537562.

Conflict of interest statement

Competing Interests: Kristina Gemzell-Danielsson has received honoraria for serving on medical advisory boards of Bayer Pharma AG. Thirty LNG-IUS devises were received from Bayer Pharma AG. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1. Study flow chart.
Figure 1. Study flow chart.
Randomization and follow up of Study Participants. Women who missed an evaluation could return for later follow-up visits.

References

    1. Henshaw RC, Naji SA, Russell IT, Templeton AA (1993) Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 89: 714–717.
    1. Winikoff B (1995) Acceptability of medical abortion in early pregnancy. Fam Plann Perspect 185: 142–148.
    1. Fiala C, Gemzell-Danielsson K (2006) Review on medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception 74: 66–68.
    1. Heikinheimo O, Gissler M, Suhonen S (2008) Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. Contraception 78: 149–154.
    1. Heikinheimo O, Gissler M, Suhonen S (2009) Can the outcome of the next pregnancy be predicted at the time of induced abortion? Hum Reprod 24: 820–826.
    1. Roberts H, Silva M, Xu S (2010) Post abortion contraception and its effect on repeat abortion in Auckland, New Zealand. Contraception 82: 260–265.
    1. Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A (2008) Impact of immediate postabortal insertion of IUC on repeat abortion. Contraception 78: 143–148.
    1. Grimes DA, Lopez LM, Schulz KF, Stanwood NL (2010) Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 6: CD001777.
    1. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, et al. (2012) Effectiveness of long-acting reversible contraception. N Engl J Med 366: 1998–2007.
    1. Schreiber CA, Sober S, Ratcliffe S, Creinin M (2011) Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception 84: 230–233.
    1. Lähteenmäki P, Luukkainen T (1978) Return of ovarian function after abortion. Clin Endocrinol 8: 123–132.
    1. Boesen HC, Rorbye C, Norgaard M, Nilas L (2004) Sexual behavior during the first eight weeks after legal termination of pregnancy. Acta Obstet Gynecol Scand 83: 1189–1192.
    1. Heikkilä M, Lähteenmäki P, Luukkainen T (1982) Immediate postabortal insertion of a levonorgestrel-releasing IUD. Contraception 26: 245–259.
    1. Pakarinen P, Toivonen J, Luukkainen T (2003) Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception 68: 31–34.
    1. Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, et al. (2011) Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med 364: 2208–2217.
    1. Gillett PG, Lee NH, Yuzpe AA, Cerskus I (1980) A comparison of the efficacy and acceptability of the Copper-7 intrauterine device following immediate or delayed insertion after first-trimester therapeutic abortion. Fertil-Steril 34: 121–124.
    1. Betstadt SJ, Turok DK, Kapp N, Feng KT, Borgatta L (2010) Intrauterine device insertion after medical abortion. Contraception 83: 517–521.
    1. Shimoni N, Davis A, Ramos ME, Rosario L, Westhoff C (2011) Timing of Copper Intrauterine Device Insertion After Medical Abortion. Obstet & Gynecol 118: 623–628.
    1. Grossman D, Grindlay K (2011) Alternatives to ultrasound for follow-up after medical abortion: a systematic review. Contraception 83: 504–510.
    1. Cameron ST, Glasier A, Dewart H, Johnstone A, Burnside A (2012) Telphone follow-up and self-performed urine pregnancy testing after early medical abortion: a service evaluation. Contraception 86: 67–73.
    1. Rybo G, Andersson K, Odlind V (1993) Hormonal intrauterine devices. Annals of Medicine 25: 143–147.
    1. Mansour D, Gmezell-Danielsson K, Inki P, Jensen JT (2011) Fertility after discontinuation of contraception: a comprehensive review of the literature. Contraception 84: 465–477.
    1. Sääv I, Aronsson A, Stephansson O, Gemzell-Danielsson K (2007) Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 22: 2647–2652.
    1. Marions L, Lövkvist L, Taube A, Johansson M, Dalvik H, et al. (2011) Use of the levonorgestrel releasing-intrauterine system in nulliparous women–a non-interventional study in Sweden. Eur J Contracept Reprod Health Care 16: 126–134.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit